Future generation of combined multimodal approach to treat brain glioblastoma multiforme and potential impact on micturition control
© 2021 Xiao Xue Zeng et al., published by De Gruyter, Berlin/Boston..
Glioblastoma remains lethal even when treated with standard therapy. This review aims to outline the recent development of various advanced therapeutics for glioblastoma and briefly discuss the potential impact of glioblastoma and some of its therapeutic approaches on the neurological function micturition control. Although immunotherapy led to success in treating hematological malignancies, but no similar success occurred in treatment for brain glioblastoma. Neither regenerative medicine nor stem cell therapy led to astounding success in glioblastoma. However, CRISPR Cas system holds potential in multiple applications due to its capacity to knock-in and knock-out genes, modify immune cells and cell receptors, which will enable it to address clinical challenges in immunotherapy such as CAR-T and regenerative therapy for brain glioblastoma, improving the precision and safety of these approaches. The studies mentioned in this review could indicate that glioblastoma is a malignant disease with multiple sophisticated barriers to be overcome and more challenges might arise in the attempt of researchers to yield a successful cure. A multimodal approach of future generation of refined and safe therapeutics derived from CRISPR Cas therapeutics, immunotherapy, and regenerative therapeutics mentioned in this review might prolong survival or even contribute towards a potential cure for glioblastoma.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Reviews in the neurosciences - 33(2022), 3 vom: 26. Apr., Seite 313-326 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zeng, Xiao Xue [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CAR-T |
|---|
| Anmerkungen: |
Date Completed 05.04.2022 Date Revised 31.05.2022 published: Electronic-Print Citation Status MEDLINE |
|---|
| doi: |
10.1515/revneuro-2021-0068 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330718835 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330718835 | ||
| 003 | DE-627 | ||
| 005 | 20231225211903.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/revneuro-2021-0068 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1102.xml |
| 035 | |a (DE-627)NLM330718835 | ||
| 035 | |a (NLM)34529907 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zeng, Xiao Xue |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Future generation of combined multimodal approach to treat brain glioblastoma multiforme and potential impact on micturition control |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.04.2022 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 Xiao Xue Zeng et al., published by De Gruyter, Berlin/Boston. | ||
| 520 | |a Glioblastoma remains lethal even when treated with standard therapy. This review aims to outline the recent development of various advanced therapeutics for glioblastoma and briefly discuss the potential impact of glioblastoma and some of its therapeutic approaches on the neurological function micturition control. Although immunotherapy led to success in treating hematological malignancies, but no similar success occurred in treatment for brain glioblastoma. Neither regenerative medicine nor stem cell therapy led to astounding success in glioblastoma. However, CRISPR Cas system holds potential in multiple applications due to its capacity to knock-in and knock-out genes, modify immune cells and cell receptors, which will enable it to address clinical challenges in immunotherapy such as CAR-T and regenerative therapy for brain glioblastoma, improving the precision and safety of these approaches. The studies mentioned in this review could indicate that glioblastoma is a malignant disease with multiple sophisticated barriers to be overcome and more challenges might arise in the attempt of researchers to yield a successful cure. A multimodal approach of future generation of refined and safe therapeutics derived from CRISPR Cas therapeutics, immunotherapy, and regenerative therapeutics mentioned in this review might prolong survival or even contribute towards a potential cure for glioblastoma | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a CAR-T | |
| 650 | 4 | |a CRISPR Cas system | |
| 650 | 4 | |a glioblastoma | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a micturition | |
| 650 | 4 | |a regenerative medicine | |
| 650 | 7 | |a Receptors, Chimeric Antigen |2 NLM | |
| 700 | 1 | |a Zeng, Jianwen |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Baoyi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Reviews in the neurosciences |d 1987 |g 33(2022), 3 vom: 26. Apr., Seite 313-326 |w (DE-627)NLM074824201 |x 2191-0200 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2022 |g number:3 |g day:26 |g month:04 |g pages:313-326 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1515/revneuro-2021-0068 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2022 |e 3 |b 26 |c 04 |h 313-326 | ||